Invasive fungal infections (IFIs) are a major cause of morbidity and mortality in patients with hematological malignancies during prolonged episodes of neutropenia precipitated by chemotherapy ([@b1-idmm-25-299]). To combat this predisposition to IFI in this group of patients, multiple strategies have been used, namely prophylaxis, preemptive and empirical treatments. There are several candidate antifungals available for use including the polyenes and echinocandins. In empirical antifungal therapy in febrile neutropenic patients, two key properties are desired: efficacy and reduced toxicity. Although amphotericin B and its lipid formulations have been used as empirical treatments for high-risk febrile neutropenic patients, their unfavourable side effect profile is an impediment. Over the past decade, caspofungin, an echinocandin, was found to be noninferior to amphotericin B and liposomal amphotericin B in treatments of invasive candidiasis and persistent fever and neutropenia, respectively ([@b2-idmm-25-299],[@b3-idmm-25-299]). As a result, the echinocandins were promptly included in recommendations for treatment of invasive candidiasis by the Infectious Diseases Society of America ([@b4-idmm-25-299]). Caspofungin was also approved in empirical antifungal treatment of febrile neutropenic patients ([@b1-idmm-25-299],[@b5-idmm-25-299]).

There is a paucity of data regarding the use of micafungin as empirical antifungal treatment in febrile neutropenic patients with hematological malignancies. Kubiak et al ([@b6-idmm-25-299]) evaluated the use of micafungin compared with caspofungin as antifungal treatment in persistently febrile neutropenic patients in a sequential retrospective cohort. Similar efficacy was observed in terms of survival, treatment of baseline IFIs (despite a small number) and incidence of breakthrough fungal infections. However, the data were limited by the fact that prolonged neutropenia (an established risk factor for invasive fungal infections, as per European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group \[EORTC-MSG\] criteria and the Infectious Diseases Society of America) was not a prerequisite to include patients in the analysis, especially because IFIs are less likely to develop early during chemotherapy-induced neutropenia ([@b1-idmm-25-299],[@b5-idmm-25-299]). The other limiting factor was the inclusion of patients who received as few as two doses of caspofungin or micafungin, which may not reflect true efficacy. This may have affected the outcome of the analysis.

Therefore, we conducted the present retrospective cohort study to compare micafungin (at a dose of 100 mg intravenously once per day) with caspofungin (loading dose of 70 mg followed by 50 mg once per day) for the treatment of febrile patients with persistent neutropenia who have hematological malignancies (prolonged neutropenia for ≥10 days), thus being at higher risk to develop IFI. By establishing a minimum standard of five days of antifungal therapy, we hoped to increase the robustness of the conclusions drawn from the present cohort analysis.

METHODS
=======

Study design
------------

A retrospective cohort analysis involving patients with acute leukemia admitted to the Princess Margaret Cancer Centre (University Health Network, Toronto, Ontario) between April 2005 and November 2009 was conducted. All patients reviewed had received empirical antifungal therapy with either caspofungin or micafungin for persistent fever during a period of profound neutropenia. Caspofungin was the sole echinocandin used for persistent fever until June 2008, when micafungin was introduced as therapy for persistent fever in profoundly neutropenic patients. After that date, both agents were used for this indication. Patients were identified through the Department of Pharmacy dispensing records at the hospital and were enrolled in a 1:2 manner for micafungin versus caspofungin. Approval for data collection was obtained from the Research Ethics Board of the University Health Network (Toronto, Ontario).

Patients
--------

Patients diagnosed with hematological malignancies housed in specific patient wards at the Princess Margaret Cancer Centre and who received caspofungin or micafungin were initially identified from pharmacy records. Thereafter, patients were only identified by their medical record number and data were retrieved from the electronic patient record. To be included in the present study, patients had to meet stipulated criteria: have a hematological malignancy; undergo induction, reinduction for failed remission or relapse, or consolidation chemotherapy, or have myelodysplastic syndrome (MDS) treated with azacytadine; be profoundly neutropenic, defined by \<0.5×10^9^ neutrophils/L for a minimum of 10 days; and be treated with caspofungin or micafungin for a minimum of five days. Patients lacking these prespecified criteria were excluded.

The following information was collected: age; sex; length of hospital stay; duration of neutropenia (the first day the neutrophil count fell to \<0.5×10^9^/L cells was considered to be day 1 of neutropenia, and the first day of neutrophil recovery ≥0.5×10^9^/L cells was considered to be the end of the neutropenic period); primary diagnosis (acute myeloid leukemia, acute lymphoblastic leukemia \[ALL\], MDS, chronic myeloid leukemia); antifungal prophylaxis (drug and dose); type of chemotherapy (induction, reinduction or consolidation); chemotherapeutic agents; duration of neutropenia; start and end date of systemic antifungal therapy; computed tomography (CT) scan studies; treatment of baseline fungal infection; adverse events related to caspofungin and micafungin necessitating discontinuation of therapy; survival; and breakthrough fungal infections.

Data regarding the systemic empirical antifungal treatments were accrued as follows: the day on which either antifungal treatment was started was considered to be day 0; and assessments were performed again for each patient at days three to five of therapy, two weeks and four weeks. These assessments were documented as first, second and third reassessments, respectively.

Treatment outcomes
------------------

A composite end point was evaluated for each antifungal treatment course of micafungin and caspofungin, respectively. Antifungal treatment success reflected survival at seven days of antifungal treatment, successful treatment of baseline fungal infections, absence of adverse events due to the antifungal medication and the absence of breakthrough fungal infections. Fever, which is usually included as one of the variables of the composite end point, was not assessed due to the lack of consistent temperature records in the electronic patient record. Therefore, fever was not included as part of the composite end point.

Baseline fungal infection was defined as a fungal infection that was already identified on inclusion in the study or within 48 h of starting micafungin or caspofungin. Breakthrough fungal infection was defined as a fungal infection diagnosed \>48 h after starting antifungal treatment.

IFIs were defined according to the revised EORTC-MSG criteria ([@b7-idmm-25-299]). However, a possible IFI was determined on the basis of historical commentary of persistent fever unresponsive to appropriate antibacterial therapy with CT imaging findings consistent with pulmonary infection that did not meet the prespecified CT scan findings outlined in the EORTC-MSG criteria ([@b7-idmm-25-299]). Abnormal chest CT findings similar to those previously documented by others were considered to be consistent with IFI ([@b8-idmm-25-299]). The diagnosis of presumed fungal infection was made based on the presence of infectious symptoms of presumed fungal origin, regardless of whether antifungal prophylaxis was being administered, because appropriate antibacterial therapy was being used and there was no obvious focus of infection documented.

Statistical analysis
--------------------

Demographic information for the treatment groups was assessed and compared using χ^2^ tests for categorical variables, Student's *t* test for normally distributed continuous variables and rank-sum test for non-normally distributed continuous variables. Overall success rates between the treatment groups were evaluated on the basis of the four parameters comprising the composite end point as stated above. Differences between the groups in overall success and each of the four end points were evaluated using χ^2^ testing. All analyses were performed using Stata version 12. A forest plot was generated using R version 3.1.0 and the 95% CIs for the absolute difference between the treatment groups were calculated using a Cochran-Mantel Haenszel method ([@b9-idmm-25-299]).

RESULTS
=======

The investigators initially identified 340 patients through retrospective chart review, who received echinocandin therapy with caspofungin or micafungin for fever and neutropenia during the study period. The disposition of the patients is illustrated in [Figure 1](#f1-idmm-25-299){ref-type="fig"}. A total of 92 and 118 patients were excluded from the caspofungin and micafungin groups, respectively. Reasons for exclusions were: duplicate entries; neutropenia for \<10 days; receipt of the study drug for \<5 days; or receipt of the study drug concomitantly with another agent. Patients who received interrupted courses of the study drug or received it while non-neutropenic, and those who were stem cell transplant recipients were also excluded. In addition, 58 patients were excluded from the micafungin group because they received prophylactic micafungin at a dose of 50 mg per day.

The demographic characteristics of the patients analyzed in the study are summarized in [Table 1](#t1-idmm-25-299){ref-type="table"}. The median ages of the patients were 47 and 54 years of age in the micafungin and caspofungin groups, respectively (P=0.02). There was no difference in the sex distribution between the groups, with 56% (27 of 48) and 61% (50 of 82) being male in the micafungin and the caspofungin groups, respectively (P=0.6). The median length of admission was similar in both groups (36 days in the micafungin and 39 days in the caspofungin patients; P=0.8). Other baseline demographic characteristics were similar in both groups. The most common underlying diagnosis was acute myeloid leukemia (79% \[38 of 48\] in the micafungin group and 83% \[68 of 82\] in the caspofungin group). The remaining diagnoses were ALL, relapsed ALL and MDS. There were no significant differences in chemotherapeutic regimens used for the patients. Forty percent (19 of 48) of the micafungin group compared with 54% (44 of 82) of the caspofungin patients received induction regimens, while 42% (20 of 48) versus 30% (25 of 82) received reinduction chemotherapy. The remainder received consolidation treatment. The median duration of neutropenia was similar in in the micafungin and caspofungin groups (25 days and 29 days, respectively; P=0.7).

Seventy-three percent (35 of 48) of the patients in the micafungin group received antifungal prophylaxis, in contrast to 57% (47 of 82) of the patients in the caspofungin group (P=0.08). Of the 48 patients who received antifungal prophylaxis in the micafungin group, 31 received fluconazole, while three received micafungin 50 mg and one received voriconazole ([Table 2](#t2-idmm-25-299){ref-type="table"}). In the caspofungin group, 38 of 82 received fluconazole, one received caspofungin, five received voriconazole, one received itraconazole and two received amphotericin B. Caspofungin prophylaxis was provided to one patient in the caspofungin group for seven days before the development of neutropenia; the patient was then transitioned to empirical antifungal therapy. No baseline fungal infection was noted; however, the patient subsequently developed pulmonary CT findings indicative of a possible breakthrough infection and was considered to represent a failure. All patients received antibacterial agents for their febrile neutropenic episode, but no significant differences were noted between the two groups. In addition, there was a minority of patients in each group (nine in the micafungin group and 19 in the caspofungin group) who required previous antifungal therapy due to presumed fungal infection but were judged to have failed this therapy due to ongoing infectious symptoms and/or abnormal radiological findings and were, thus, placed on one of the study medications.

Treatment outcomes
------------------

The median duration of therapy for the micafungin and caspofungin groups was 16 days and 14.5 days, respectively (P=0.62) ([Table 1](#t1-idmm-25-299){ref-type="table"}). As mentioned above, a successful treatment outcome was adjudicated based on four parameters: survival ≥7 days after the discontinuation of antifungal therapy; treatment of baseline fungal infection; absence of breakthrough fungal infections; and absence of discontinuation of antifungal therapy due to adverse events. The treatment outcomes are summarized in [Table 3](#t3-idmm-25-299){ref-type="table"}. Both drugs performed similarly in all parameters except for survival. All patients in the micafungin group (100% \[48 of 48\]) survived for a minimum of seven days after discontinuation of micafungin compared with 89% (73 of 82) in the caspofungin group (P=0.02). As mentioned previously, all fungal infections were categorized according to the EORTC-MSG criteria as proven, probable and possible infections ([@b7-idmm-25-299]). The modified CT findings of the chest indicating a fungal infection, as described by others ([@b8-idmm-25-299]), were also adopted. Baseline fungal infections were defined as those diagnosed before or within 72 h after starting the study antifungal. There were no proven or probable baseline fungal infections among the micafungin patients. However, there were 19 patients (40%) with possible IFIs at baseline and the remaining patients (n=29) received micafungin as empirical treatment (60%) for various symptoms (predominantly fever). In the caspofungin group, there were three (4%) proven baseline infections (P=0.18). All were candidemias due to *Candida albicans* and all responded to the therapy. No patients in the caspofungin group had a probable fungal infection, while 56% (46 of 82) had a possible fungal infection (P=0.07 compared with micafungin) and the remaining 40% (33 of 82) (P=0.03) received caspofungin as empirical antifungal treatment. Overall, baseline fungal infections (proven, probable and possible) were successfully treated in eight (42%) patients in the micafungin treatment group compared with 26 (53%) in the caspofungin group (P=0.42).

Breakthrough IFI was once again classified as per the EORTC-MSG criteria as proven, probable and possible infection ([@b7-idmm-25-299]). There were three proven breakthrough IFIs (three of 48 \[6%\]) among the micafungin therapy patients (two candidemias cause by *Candida parapsilosis* and one biopsy-proven mucormycosis of the skin). No probable IFIs were observed in the micafungin-treated patients. However, eight (17%) of 48 patients were classified as having possible IFIs with no identifiable pathogen noted. Thirty-seven (77%) individuals had no breakthrough fungal infections. In contrast, none of the caspofungin-treated patients developed a proven (P=0.02) or probable IFI. A possible breakthrough IFI occurred in 11 (13%) (P=0.61); while 71 of the 82 patients (86.6%) had no breakthrough IFI; this was not statistically significant compared with the micafungin group (P=0.16) ([Table 3](#t3-idmm-25-299){ref-type="table"}).

No adverse events led to discontinuation of micafungin, whereas caspofungin therapy had to be stopped in one of the 82 patients (1.2%) due to an adverse event manifested by elevated liver enzymes (aspartate aminotransferase \>5 times the baseline value) (P=0.44) ([Table 3](#t3-idmm-25-299){ref-type="table"}).

Failure in any of the four parameters used to assess successful therapy resulted in determining failure of the course of empirical therapy for either antifungal agent. Thus, the overall success rate for micafungin was 60.4% (29 of 48), whereas for caspofungin it was 57.3% (47 of 82) (P=0.729). The absolute differences between the micafungin and caspofungin patient groups (95% CIs) with regard to each end point as well as overall success are presented in [Figure 2](#f2-idmm-25-299){ref-type="fig"}.

DISCUSSION
==========

Prompted by the high rate of IFIs in patients with acute leukemia and the subsequent morbidity and mortality of these infections in persistently febrile neutropenic patients ([@b10-idmm-25-299]), empirical antifungal therapy, aimed at targeting the most commonly encountered fungal pathogens (ie, *Candida* and *Aspergillus* species), is a commonly used strategy for managing persistently febrile neutropenic patients ([@b1-idmm-25-299]). One of the options for empirical antifungal therapy is the echinocandins. The echinocandins, caspofungin ([@b3-idmm-25-299]), micafungin ([@b11-idmm-25-299]) and anidulafungin ([@b12-idmm-25-299]), have demonstrated efficacy against *Candida*. Moreover, caspofungin, anidulafungin and micafungin have demonstrated efficacy in treating invasive aspergillosis alone or in combination with other antifungal agents ([@b13-idmm-25-299]--[@b15-idmm-25-299]). Although micafungin was shown to be superior to fluconazole when used for primary antifungal prophylaxis in stem cell transplant recipients, with reduction in the rate of breakthrough invasive *Aspergillus* infections in the micafungin arm ([@b16-idmm-25-299]), the optimal micafungin dose to be used in treating invasive aspergillosis is still unknown ([@b15-idmm-25-299]). Due to its lower wholesale noncontractual drug acquisition cost compared with caspofungin, micafungin offers a potential advantage.

However, while caspofungin has been approved as an empirical antifungal treatment for persistently febrile neutropenic cancer patients, the efficacy of micafungin for that indication is still unproven. This issue prompted Kubiak et al ([@b6-idmm-25-299]) to explore the use of micafungin as an empirical antifungal therapy in febrile neutropenic patients in a retrospective study. That study, however, had a number of limitations: specifically, a heterogeneous patient population with varying degrees and durations of neutropenia, as previously mentioned. We mandated a 10-day minimum duration of neutropenia for inclusion, which is the duration associated with the development of fungal infections ([@b1-idmm-25-299]). Moreover, a minimum duration of five days of treatment in each arm was required for inclusion to ensure proper assessment for efficacy and side effects. In the present retrospective study, we demonstrated that micafungin had a similar overall efficacy compared with caspofungin when used for treating persistently neutropenic patients with acute leukemia (overall efficacy of 60.4% for micafungin versus 57.3% for caspofungin). Efficacy was substantiated in a robust fashion by using four of five efficacy end points based on previously used criteria to evaluate and compare efficacy of antifungals for this purpose ([@b2-idmm-25-299],[@b17-idmm-25-299],[@b18-idmm-25-299]). With regard to the evaluation parameters and a comparison of the treatment groups, proven baseline fungal infections were all candidemias, and occurred only in the caspofungin group, all of which were successfully treated. We also included possible baseline IFIs to enhance our results, demonstrating response rates of 42% in the micafungin group and 53% with caspofungin (P=0.42). This was performed in an attempt to provide additional information about the patients' disposition. Breakthrough infections occurred only in the micafungin group; two were *C parapsilosis* candidemias, an expected breakthrough infection considering the well-documented inherent increased minimum inhibitory concentrations of *C parapsilosis* species to echinocandins ([@b19-idmm-25-299]). The third was due to biopsy-proven mucormycosis of the skin -- once more, a weakness in the antifungal coverage of the echinocandins ([@b19-idmm-25-299]). Although our data demonstrate similar efficacy of micafungin compared with caspofungin when used to treat persistently neutropenic patients, one may question the robustness of this conclusion given the exclusion of fever as an end point. Nonetheless, the utility of including fever as a primary composite end point has been questioned by investigators, primarily due to the lack of specificity of fever as a sign of occult fungal infection, particularly in the studied population ([@b20-idmm-25-299],[@b21-idmm-25-299]) and its lack of accuracy as a harbinger for IFI ([@b22-idmm-25-299],[@b23-idmm-25-299]).

We acknowledge that the present study had some other limitations. The retrospective nature limited the ability to control for all the potential confounding factors, although the cohort design lessened this issue somewhat. There were also few proven baseline fungal infections and all occurred in the caspofungin group. In addition, there were no proven mold infections among the included patients, which makes drawing firm conclusions regarding the efficacy of micafungin to treat mold infections impossible. Furthermore, surrogate markers for invasive mold infection, such as galactomannan assays, were not available at the institution at the time of patients' hospitalizations, which may partially explain the high number of possible IFIs and the absence of probable IFIs. The lack of adherence to the standardized EORTC-MSG radiological criteria in our study may be viewed as another limitation. However, strict adherence to these radiological criteria may result in unnecessary exclusion of patients from trials that assess efficacy of antifungal therapies in treating IFIs in neutropenic populations, as previously suggested ([@b8-idmm-25-299]). To substantiate false identification of patients with bacterial respiratory tract infections as possible invasive pulmonary fungal infections, all patients with possible or probable infections based on abnormal radiological findings had negative sputum or bronchoalveolar lavage bacterial cultures at the time of inclusion.

CONCLUSION
==========

Micafungin demonstrated similar efficacy to caspofungin when used to empirically treat febrile neutropenic patients with hematological malignancies, as shown by the composite end point. Our study also substantiates the safety profile of micafungin at a dose of 100 mg. A prospective, randomized clinical trial comparing caspofungin and micafungin for treatment of persistently febrile neutropenic patients with focus on outcomes with mold infections is warranted.
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###### 

Demographic data

  **Variable**                                            **Micafungin (n=48)**   **Caspofungin (n=82)**   **P**
  ------------------------------------------------------- ----------------------- ------------------------ -------
  Mean age, years                                         47                      54                       0.02
  Sex                                                                                                      
    Male                                                  27 (56)                 50 (61)                  0.6
    Female                                                21 (44)                 32 (39)                  
  Duration of study drug, days, median (IQR)              16 (10--22.5)           14.5 (9--23)             
  Length of hospital stay, days, median                   36                      39                       0.8
  Primary diagnosis                                                                                        
    Acute myeloid leukemia                                38 (79)                 68 (83)                  0.51
    Acute lymphoblastic leukemia                          9 (19)                  12 (15)                  
    Other^[\*](#tfn2-idmm-25-299){ref-type="table-fn"}^   1 (2)                   2 (2)                    
  Chemotherapeutic regimen                                                                                 
    Induction chemotherapy                                19 (40)                 44 (54)                  0.21
    Reinduction chemotherapy                              20 (42)                 25 (30)                  0.2
    Consolidation chemotherapy                            2 (4)                   6 (7)                    0.47
  Duration of neutropenia, days, median (IQR)             25 (19.5, 36)           29 (19, 38)              0.7
  Previous antifungal prophylaxis                         35 (73)                 47 (57)                  0.08

Data presented as n (%) unless otherwise indicated.

Chronic myeloid leukemia, aplastic anemia, myelodysplastic anemia. IQR Interquartile range

###### 

Antifungal prophylaxis

  **Prophylaxis agent**                                      **Micafungin (n=48)**   **Caspofungin (n=82)**   **P**
  ---------------------------------------------------------- ----------------------- ------------------------ -------
  Fluconazole                                                31                      38                       0.34
  Micafungin^[\*](#tfn3-idmm-25-299){ref-type="table-fn"}^   3                       0                        0.04
  Caspofungin                                                0                       1                        0.39
  Amphotericin B                                             0                       2                        0.22
  Voriconazole                                               1                       5                        0.18
  Itraconazole                                               0                       1                        0.39

Micafungin dose 50 mg intravenously once per day

###### 

Treatment outcomes

  **Treatment outcome**                                                          **Micafungin (n=48)**   **Caspofungin (n=82)**   **P**
  ------------------------------------------------------------------------------ ----------------------- ------------------------ -------
  Survival ≥7 days after stopping antifungal agent                               48 (100)                73 (89)                  0.02
  Successful treatment of baseline infections                                    8/19 (42)               26/49 (53)               0.42
    Proven baseline infection[^\*^](#tfn5-idmm-25-299){ref-type="table-fn"}      0 (0)                   3 (3.7)                  0.18
    Possible baseline infection                                                  19 (39.6)               46 (56.1)                0.07
    No baseline infections                                                       29 (60.4)               33 (40.2)                0.03
  Breakthrough fungal infections                                                 11 (23)                 11 (13.4)                0.06
    Proven breakthrough infection^[†](#tfn6-idmm-25-299){ref-type="table-fn"}^   3 (6)                   0 (0)                    0.02
    Possible breakthrough infection                                              8 (17)                  11 (13)                  0.61
    None                                                                         37 (77)                 71 (87)                  0.16
  Absence of adverse events^[‡](#tfn7-idmm-25-299){ref-type="table-fn"}^         48 (100)                81 (99)                  0.44
  Overall success                                                                                                                 
    Yes                                                                          29 (60.4)               47 (57.3)                0.73
    No                                                                           19 (39.6)               54 (41.5)                

Data presented as n (%) unless otherwise indicated.

*All proven baseline infections are due to* Candida albicans *candidemia;*

*Two cases of* Candida parapsilosis *and one case of mucormycosis of the skin;*

Defined as aspartate aminotransferase \>5 times the upper limit of normal
